OMEGA-3 FATTY ACIDS

Summary

Omega-3 Fatty Acids (CHEMBL4298065) is a phase-3 clinical-stage unknown (ATC A05BA10); indicated across 30 conditions including aids and chronic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: A05BA10
• Indications: 30 conditions
• Clinical trials: 209

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298065
Name	OMEGA-3 FATTY ACIDS
Type	Unknown
Max phase	3
ATC	A05BA10

Also known as: NDI 441, Omega 3 fatty acids, Omega-3, Omega-3 acid, Omega-3 acid triglycerides, Omega-3 acids, Omega-3 fatty acids, Omega-3 phospholipids, Omega-3 polyunsaturates, Omega-3 triglycerides, Phospholipids, OMEGA-3 FATTY ACIDS

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

27 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
AIDS	3	MONDO:0012268	EFO:0000765
chronic kidney disease	3	MONDO:0005300	EFO:0003884
coronary artery disorder	3	MONDO:0005010	EFO:0001645
nicotine dependence	3	MONDO:0008575	EFO:0003768
attention deficit-hyperactivity disorder	3	MONDO:0007743	EFO:0003888
dry eye syndrome	3	MONDO:0006733	EFO:1000906
fatty liver disease	3	MONDO:0004790	HP:0001397
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
depressive disorder	3	MONDO:0002050	MONDO:0002050
epilepsy	2	MONDO:0005027	EFO:0000474
periodontitis	2	MONDO:0005076	EFO:0000649
major depressive disorder	2	MONDO:0002009	MONDO:0002009
nutritional disorder	2	MONDO:0005137	EFO:0001069
inborn error of immunity	2	MONDO:0003778	HP:0002721
bipolar disorder	2	MONDO:0004985	MONDO:0004985
sickle cell disease	2	MONDO:0011382	MONDO:0011382
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
monoclonal gammopathy	2	MONDO:0004960	EFO:0000203
Sjogren syndrome	2	MONDO:0010030	EFO:0000699
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
autism spectrum disorder	2	MONDO:0005258	EFO:0003756
peripheral arterial disease	2	MONDO:0005386	EFO:0004265
lung neoplasm	2	MONDO:0021117	MONDO:0008903
breast neoplasm	1	MONDO:0021100	MONDO:0007254
multiple sclerosis	1	MONDO:0005301	MONDO:0005301
metabolic dysfunction-associated steatotic liver disease	1	MONDO:0013209	EFO:0003095
male infertility	1	MONDO:0005372	EFO:0004248

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 209.

Phase distribution

Phase	Trials
Not specified	108
PHASE2	29
PHASE3	25
PHASE4	22
PHASE2/PHASE3	10
PHASE1	7
EARLY_PHASE1	5
PHASE1/PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00141232	PHASE4	COMPLETED	Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00396461	PHASE4	TERMINATED	ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients
NCT00396643	PHASE4	COMPLETED	Indicated Prevention With Omega-3 Fatty Acids in Adolescents With ‘At-Risk-Mental-State’ for Psychosis
NCT00758927	PHASE4	UNKNOWN	The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients
NCT00828178	PHASE4	COMPLETED	Efficacy of Fish Oil in Lupus Patients
NCT01091714	PHASE4	COMPLETED	Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?
NCT01376817	PHASE4	UNKNOWN	Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis
NCT01396486	PHASE4	COMPLETED	Inositol and Omega-3 Fatty Acids in Pediatric Mania
NCT01478776	PHASE4	UNKNOWN	The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT01744067	PHASE4	COMPLETED	The Effects of Omega-3 Fatty Acids in Renal Transplantation
NCT01896037	PHASE4	COMPLETED	Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels
NCT02092584	PHASE4	COMPLETED	Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD.
NCT02117960	PHASE4	COMPLETED	Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD
NCT02195609	PHASE4	COMPLETED	Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
NCT02382471	PHASE4	COMPLETED	Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD
NCT02597439	PHASE4	COMPLETED	Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
NCT02642159	PHASE4	COMPLETED	Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
NCT02768636	PHASE4	COMPLETED	Can Omega-3 Improve Heart Rate Variability Measurement?
NCT03355638	PHASE4	COMPLETED	Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
NCT05711810	PHASE4	COMPLETED	Medicine-induced Cardiac Hemodialysis on COVID-19
NCT05990712	PHASE4	UNKNOWN	The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers
NCT00000473	PHASE3	COMPLETED	Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?
NCT00116857	PHASE3	COMPLETED	Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors
NCT00422266	PHASE3	COMPLETED	Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Food in Dyslipidemic Adults
NCT00480207	PHASE2/PHASE3	COMPLETED	Folic Acid and Omega -3 Fatty Acid Supplementation in Depressed Older Adults
NCT00585390	PHASE2/PHASE3	COMPLETED	Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
NCT00609180	PHASE3	TERMINATED	Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)
NCT00764010	PHASE3	COMPLETED	Diet and Omega-3 Intervention Trial on Atherosclerosis
NCT00935766	PHASE3	TERMINATED	Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
NCT00959010	PHASE3	COMPLETED	Omega 3 Supplementation in Cystic Fibrosis Patients
NCT01219244	PHASE2/PHASE3	COMPLETED	Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)
NCT01235130	PHASE3	COMPLETED	Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation
NCT01686568	PHASE3	COMPLETED	Omega-3 Fatty Acids and Insulin Sensitivity
NCT01744275	PHASE2/PHASE3	SUSPENDED	HOPE-Epilepsy Trial
NCT01745263	PHASE3	COMPLETED	DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial
NCT01764308	PHASE3	TERMINATED	Effects of Omega-3 Fatty Acid Supplementation in Acne Patients
NCT01777048	PHASE3	TERMINATED	Omega-3 Fatty Acids Supplementation in ADHD
NCT01803711	PHASE2/PHASE3	TERMINATED	Omega 3 FA Supplements as Augmentation in the Treatment of Depression
NCT01813006	PHASE3	COMPLETED	Effect of Omega-3 Fatty Acid on Endothelial Function
NCT02016079	PHASE2/PHASE3	COMPLETED	Effect of Omega-3 Supplementation on Child Behavior Problems
NCT02041520	PHASE3	COMPLETED	Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients
NCT02070211	PHASE2/PHASE3	UNKNOWN	Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
NCT02099890	PHASE3	COMPLETED	The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
NCT02128763	PHASE3	COMPLETED	Dry Eye Assessment and Management Study
NCT02152930	PHASE3	TERMINATED	The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication
NCT02192580	PHASE3	UNKNOWN	Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children
NCT02525107	PHASE3	UNKNOWN	Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
NCT02537236	PHASE3	COMPLETED	Omega-3 Supplementation in HIV Patients With Therapeutic Lifestyle Change Diet.
NCT02757872	PHASE3	COMPLETED	Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
NCT03280615	PHASE3	COMPLETED	Omega 3 Fatty Acids in Patients With Chronic Renal Disease
NCT03510715	PHASE3	COMPLETED	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
NCT03510884	PHASE3	COMPLETED	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT03627312	PHASE2/PHASE3	COMPLETED	Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders
NCT03691519	PHASE3	COMPLETED	Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells
NCT03911843	PHASE2/PHASE3	COMPLETED	Omega-3 and Vitamin D Supplements in Childhood T1D
NCT05214495	PHASE2/PHASE3	COMPLETED	Omega-3 Hydrogel and Prevention of Oral Mucositis
NCT05181189	PHASE2	NOT_YET_RECRUITING	NMDA Enhancement Combined With Omega-3 for Early Dementia
NCT07050524	PHASE2	NOT_YET_RECRUITING	Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
NCT07078344	PHASE2	RECRUITING	Omega-3D: Omega-3 for Diet-Driven Health Disparities
NCT07136519	PHASE2	NOT_YET_RECRUITING	Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
NCT07496515	PHASE2	NOT_YET_RECRUITING	Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia
NCT00000461	PHASE2	COMPLETED	Harvard Atherosclerosis Reversibility Project (HARP)
NCT00004448	PHASE2	COMPLETED	Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
NCT00010868	PHASE2	COMPLETED	Omega-3 Fatty Acids in Bipolar Disorder
NCT00312897	PHASE2	COMPLETED	Omega-3 Fatty Acids in Adolescent Depression
NCT00519779	PHASE2	COMPLETED	Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention
NCT00559156	PHASE2	COMPLETED	Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00786799	PHASE2	COMPLETED	Omega-3 Fatty Acids for Autism Treatment
NCT00854737	PHASE2	COMPLETED	Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
NCT00962598	PHASE2	COMPLETED	The Role Of Omega-3 Fatty Acids In Adolescent Depression
NCT01248728	PHASE2	COMPLETED	Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)
NCT01352013	PHASE2	COMPLETED	The Impact of Omega-3 Fatty Acid Supplements on Fibromyalgia Symptoms
NCT01399827	PHASE2	COMPLETED	Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
NCT01477697	PHASE1/PHASE2	TERMINATED	Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients
NCT01694667	PHASE2	COMPLETED	Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
NCT01831453	PHASE2	UNKNOWN	Omega-3 and Quality of Life in Recurrent Aphthous Stomatitis Patients
NCT02021669	PHASE2	COMPLETED	Omega-3 for Depression and Other Cardiac Risk Factors - 2
NCT02034266	PHASE2	COMPLETED	The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes
NCT02133664	PHASE1/PHASE2	COMPLETED	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
NCT02373579	PHASE2	COMPLETED	Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia
NCT02569307	PHASE2	COMPLETED	Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
NCT02581449	PHASE2	UNKNOWN	Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
NCT02764879	PHASE2	COMPLETED	Effect of Omega 3 on Periodontitis in Postmenopausal Women
NCT02795572	PHASE2	TERMINATED	Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy
NCT02890992	PHASE2	COMPLETED	An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT02899741	PHASE2	UNKNOWN	Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study
NCT03784963	PHASE1/PHASE2	TERMINATED	Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
NCT03926351	PHASE2	UNKNOWN	High Dose Omega 3 in People at Risk for Dementia
NCT00399282	PHASE1	COMPLETED	Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis
NCT00620672	PHASE1	COMPLETED	N-3 Fatty Acid Requirements for Human Development
NCT01341925	PHASE1	COMPLETED	Omega-3 and Therapy Study for Depression
NCT01381354	PHASE1	COMPLETED	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)
NCT01507753	PHASE1	COMPLETED	Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified
NCT02103842	PHASE1	COMPLETED	Omega-3 Fatty Acids to Combat Sarcopenia
NCT02278965	PHASE1	COMPLETED	Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
NCT00350194	EARLY_PHASE1	UNKNOWN	The Effects of Omega-3 Fatty Acids on Metabolic Syndrome
NCT01863576	EARLY_PHASE1	COMPLETED	Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy
NCT02719587	EARLY_PHASE1	COMPLETED	Dietary Supplementation With Low-Dose Omega-3 Reduces Salivary TNF-α Levels in Patients With Chronic Periodontitis
NCT03204266	EARLY_PHASE1	COMPLETED	Oral Supplementation to Enhance Recovery Pilot Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).